Research Article

Integrative Bioinformatics Analysis Reveals That miR-524-5p/MEF2C Regulates Bone Metastasis in Prostate Cancer and Breast Cancer

QingHua Tian, YingYing Lu, BiCong Yan, and ChunGen Wu

Department of Diagnostic and Interventional Radiology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

Correspondence should be addressed to ChunGen Wu; wucgsh@163.com

Received 6 June 2022; Accepted 28 July 2022; Published 10 September 2022

Academic Editor: Lei Chen

Copyright © 2022 QingHua Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Bone metastases are highly prevalent in patients with advanced prostate cancer and breast cancer and have a serious impact on the survival time and quality of life of these patients. It has been reported that microRNAs (miRNAs) are expressed abnormally in different types of cancer and metastases. However, it remains unknown whether the underlying miRNAs are associated with prostate and breast cancer bone metastasis. Differentially expressed miRNAs (DE-miRNAs) and their potential targets in the metastatic process were identified by bioinformatics analysis. Additionally, qPCR confirmed that the miR-524-5p expression was downregulated in prostate and breast cancer cells. The overexpression of miR-524-5p restrained cell proliferation, invasion, and metastasis in prostate and breast cancer cells. Meanwhile, miR-524-5p could target and inhibit the expression of MEF2C, which was verified by a luciferase assay. In conclusion, our data strongly suggest that downregulation of miR-524-5p appears to be a precocious event in prostate and breast cancer, and the miR-524-5p/MEF2C axis plays a novel role in bone metastases from prostate and breast cancers.

1. Introduction

Prostate cancer and breast cancer are the two most common invasive cancers in men and women, respectively. Although these two cancers arise from different organs, they are typically hormone-dependent and have an underlying biological mechanism in common [1]. As cancer is a metastatic disease, hormone therapy plays an essential role in receptor-positive breast and prostate cancer. However, although hormone therapy initially has an effect on the inhibition of breast and prostate tumours, bone metastasis is still a problem for 70% of metastatic prostate and breast cancer patients [2], showing a poor prognosis. In addition, prostate cancer and breast cancer are malignancies that are destined to become metastatic if screening has been unable to identify them at an early stage before symptoms appear [3], causing a serious threat to patients’ lives.

Bone is the tissue most susceptible to metastasis in prostate cancer [4] and breast cancer [5]. Once cancer has metastasized to the bones, and numerous skeletal-related events (SREs), such as fracture, intractable pain, bone marrow aplasia, nerve compression syndrome, and spinal cord compression, occur [6], which can rarely be cured and result in significant morbidity in patients with prostate cancer and breast cancer. Despite its morbidity, bone metastasis is one of the most intriguing and complex biological processes of all oncogenic processes and consists of the three key steps of seeding, dormancy, and outgrowth [7]. All of the processes involved in metastasis and interaction with host cells can be targeted to treat bone metastasis and tumor progression in prostate cancer and breast cancer.

MicroRNAs (miRNAs or miRs-), which are 21–25 nucleotides long, are single-stranded noncoding RNAs that are evolutionarily conserved and endogenously produced. miRNAs play an essential role in targeting the 3′ untranslated region (3′ UTR) of mRNAs, mainly to repress their expression [8]. Over the past several years, many miRNAs have been found and characterized in the pathogenesis of
many human malignancies, including critical chemokines and cytokines in the bone metastasis microenvironment [9, 10]. For example, it was reported that miR-124 could inhibit bone metastasis by inhibiting interleukin-11 in breast cancer [11]. miR-133a-3p represses bone metastasis of prostate cancer [12]. In addition, the occurrence and development of many kinds of cancer, such as colon cancer [13], melanoma [14], gastric cancer [15], osteosarcoma [16], ameloblastoma [17], and particularly breast cancer [18], are highly associated with the abnormal expression of miRNAs. Jin et al. identified miR-524-5p as a tumor suppressor. Moreover, miR-524-5p inhibited cell migration, invasion, and epithelial–mesenchymal transition and progression in breast cancer [18]. However, little is known about its function in bone metastases of prostate and breast cancer.

Here, for the first time, we revealed the role of cancer cell-derived miR-524-5p in bone metastases of prostate cancer and breast cancer. Perturbation of the miR-524-5p/MEF2C regulatory axis contributes to bone metastasis in prostate cancer and breast cancer. These results might provide novel therapeutic and diagnostic targets for bone metastases of breast cancer and prostate cancer.

2. Materials and Methods

2.1. Download of mRNA and miRNA Expression Profiles. The expression of genes and miRNAs between patients with primary prostate and breast cancer with bone metastatic prostate and breast cancer was compared. The Gene Expression Omnibus ( GEO) database (https://www.ncbi.nlm.nih.gov/geo/) was employed to obtain the gene expression profiles and the miRNA expression profile. One dataset, GSE32269, deposited by Cai et al. [19], contains 22 primary prostate cancer (hormone-dependent) versus 29 metastatic prostate cancer samples. Another dataset, GSE137842, was submitted by Lefley et al. [20] and contains 3 primary breast cancer and 3 breast cancer bone metastasis samples. These two datasets were acquired from the Affymetrix Human Genome U133 Plus 2.0 Array. The miRNA microarray dataset GSE26964 [21] was composed of 6 primary prostate cancer samples and 7 prostate cancer bone metastatic samples (platform: Capitalbio mammal microRNA V3.0).

2.2. Identification of Differentially Expressed miRNAs and mRNAs. Herein, the mRNA and miRNA expression profile data preprocessing mainly consists of background correction, quantile normalization, and probe summarization [22]. Then, limma package in bioconductor was used to extract differentially expressed miRNAs (DE-miRNAs) and differentially expressed genes (DEGs) [23] following criterion P value <0.05 and |log₂ foldchange| > 1.

2.3. GO and KEGG Pathway Annotation. The online tool of Database for Annotation and Visualization and Integrated Discovery (DAVID) was used to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment of the identified common DEGs and DE-miRNAs [24, 25]. GO analysis was conducted for the cellular component (CC), biological process (BP), molecular function (MF) categories [26], and KEGG pathway enrichment analysis for the selected genes [27]. All parameters were set as default, and P value <0.01 was considered significant.

2.4. Construction of the miRNA–miRNA Regulation Network. miRBase, TargetScan (http://www.targetscan.org/vert_71/), miTarBase, and miRWalk databases were used to identify the number of miRNA-regulated target gene pairs. The threshold of the correlation coefficient was set as -0.3, and the significance P value was set as 0.05. The pairs supported by two or more databases were further processed and retained. Regulatory network visualization for the regulatory relationship between miRNA-mRNA was conducted using Cytoscape [28].

2.5. PPI Network and Hub Gene Analysis. The interaction of the DEGs was detected using the Search Tool for the Retrieval of Interacting Genes (STRING) database, with confidence scores > 0.7. Cytoscape was used to visualize the PPI network. Hub genes and screen modules of the PPI network were identified using the CytoHubba plug-in and Molecular Complex Detection (MCODE) plug-in, of which all of the parameters were left as the defaults. Metascape was used to analyze the genes in modules.

2.6. Cell Culture. The DU145 and LNCAP cell lines of human prostate cancer and MCF7 of breast cancer were obtained from COWELDGEN SCIENTIFIC (Coweldgen Scientific Co., Ltd., Shanghai, China). DU145 and MCF-7 cells were cultured in MEM (Invitrogen, USA) supplemented with 10% FBS (Invitrogen, USA). LNCAP was cultured in RPMI 1640 medium (Invitrogen, USA) with 10% FBS. All medium were supplemented with penicillin (100 U/ml) and streptomycin (100 mg/ml) (Biosharp, China). All cells were cultured at 5% CO₂ and 37°C humidified atmosphere.

2.7. Cell Transfection. Transfection was conducted when the cell density reached 70-80% in six-well plates. miR-524-5p mimics or NC (50 nM) was transfected into cells using Lipofectamine 3000 (Invitrogen, USA) following the manufacturer’s instructions.

2.8. RNA Extraction and qPCR Analyses. Total RNA was extracted from cell lines with TRIzol Reagent (Invitrogen, USA) following the manufacturer’s instructions. In details, total RNA (2.0 μg) was reverse transcribed using the PrimeScript TM RT reagent Kit (Takara, Japan) following the manufacturer’s instructions. cDNA was amplified and quantified on the LightCycler® 96 system (Roche, Switzerland) usingSYBR® Premix Ex Taq™ II (Takara, Japan). miRcute Plus miRNA First-Strand cDNA Kit (TianGen Biotech, Beijing, China) and SYBR Green (Takara, Japan) were used to quantify mature miRNA levels. 2^\text{-ΔΔCt} was calculated to represent the relative fold expressions. The primers are shown in Table 1.
2.9. Western Blot. Total protein was extracted from cell lysate using PMSF. Then, protein sample was quantified by bicinchoninic acid (BCA), separated by SDS-PAGE gel electrophoresis, and blocked with 5% skim milk. After that, membranes were incubated with the specific primary antibody at 4°C overnight. Membranes were washed three times using TBST and incubated with the corresponding HRP-conjugated secondary antibody for 2 h at room temperature. Enhanced chemiluminescence (PerkinElmer) was used to expose membranes after washing three times. Western blots were quantified by densitometry using ImageJ.

2.10. Dual-Luciferase Reporter Gene Assay. The 3′ UTR sequence of MEF2C containing wild-type or mutant binding sites was cloned into the pmirGLO luciferase vector. Then, the MEF2C 3′ UTR WT or MUT and miR-524-5p mimics or negative control were cotransfected using Lipofectamine 3000. After 72 h, the cell lysate was centrifuged at 12,000 rpm for 5 min to perform the Dual-Lumi Luciferase Assay (Beyotime Biotechnology, Shanghai, China). Luciferase activity was measured by an EnVision Multifunctional Microplate Reader (PerkinElmer, Germany).

2.11. Cell Counting Kit-8 (CCK-8) Assay. A 100 μL cell suspension (1 × 10^4 cells) was placed in each well of a 96-well plate. Ten microliters of CCK-8 reagent (Beyotime Biotechnology, Shanghai, China) was added to each well. The cell plate was incubated overnight. After that, the absorbance value was detected at a wavelength of 450 nm by a microplate reader (SpectraMax M5; Molecular Devices, USA).

2.12. Transwell Assay. A cell suspension (1 × 10^5 cells/ml) was prepared with serum-free medium. Then, 100 μL suspension was added to the chamber, and 600 μL of complete medium was supplied to the basolateral chamber, which was incubated overnight. Subsequently, unpenetrating cells above the chamber were removed, the chamber was fixed in 4% paraformaldehyde for 30 min and then dyed with 1% crystal violet for 10-15 min, and five randomly selected fields were captured using an inverted microscope (Olympus, Tokyo, Japan).

2.13. In Vitro 3D Model of Prostate and Breast Cancer Metastasis. The animal experiments performed in this study were approved by the Institutional Animal Care and Use Committee of ShangHai Sixth People’s Hospital. To imitate the bone metastasis microenvironment in vivo, neonatal CD-1 mice were used to build an in vitro 3D model. In detail, after CD-1 mice were sacrificed, their caudal vertebrae were separated under sterile conditions and cut in the occipital lobe to produce an arch structure [29]. Then, caudal vertebrae were washed with PBS and cocultured with DU145 cells or MCF7 cells and DU145 cells or MCF7 cells transfected with miR-524-5p mimics in a 48-well plate (5 × 10^6 cells). Cranial bones without culturing with cells were used as a negative control. The crystal violet staining experiment was performed after incubation at 37°C for 4 days. In brief, the bone fragments were removed, fixed with 95% alcohol for 10 min, washed with PBS 3 times, and stained with 5 mg/ml crystal violet for 15 min. The stained bone slices were washed with PBS 3 times and observed under an inverted microscope. Each bone slice was randomly taken from 3 different fields to count the adhered cells [30, 31].

2.14. Statistical Processing. SPSS software (22.0, US) was utilized for statistical analysis. All data were represented as mean ± SD. Statistical differences were determined by a one or two-sided Student’s t-tests or w-o-way ANOVAs. A P value <0.05 was considered statistically significant.

3. Results

3.1. Identification of DE-miRNAs and DEGs. A total of 1555 DEGs were obtained from breast cancer gene expression profiles of GSE137842, of which 625 DEGs were overexpressed and 930 DEGs were downregulated in breast cancer bone metastasis samples compared to primary breast cancer samples. Volcano plots were generated to visualize all the DEGs (Figures 1(a) and 1(b)). A total of 833 DEGs were identified from prostate cancer gene expression profiles of GSE32269, of which 522 were upregulated and 311 were downregulated in prostate cancer bone metastasis samples compared to primary prostate cancer samples. Volcano plots were generated to visualize all the DEGs (Figures 1(c) and 1(d)). A total of 88 DE-miRNAs were obtained from prostate cancer miRNA expression profiles of GSE26964, of which 52 were upregulated and 311 were downregulated in prostate cancer bone metastasis samples compared to primary prostate cancer samples. Volcano plots were generated to visualize all the DE-miRNAs (Figures 1(e) and 1(f)). We overlapped the DEGs (miRNA) screened in the prostate cancer bone metastasis dataset and breast cancer bone metastasis and identified 17 genes that were upregulated and 20 that were downregulated (Figures 1(g) and 1(h)).

3.2. Pathway and Process Enrichment Analysis of DEGs. For the selected common DEGs, pathway and process enrichment analyses were conducted through GO processes and KEGG pathways [32]. The representative top 15 clusters from the 3 categories are shown in Figure 2(a). The terms enriched in the biological process (BP) category included cardiac tissue and animal organ development, embryonic organ morphogenesis, cardiac muscle cell differentiation, bone development, and bone morphogenesis. The molecular
Figure 1: Continued.
function category demonstrated enrichment in factors involved in the extracellular exosome, collagen-containing extracellular matrix, cell-substrate adherens junction, and focal adhesion. In addition, the GO cell component category showed enrichment in cadherin binding, ribonuclease activity, retinoid binding, DNA binding, enhancer binding, and aminopeptidase activity.

The results from KEGG pathway enrichment analysis demonstrated that common DEGs were significantly involved in transcriptional misregulation in cancer, parathyroid hormone synthesis secretion and action, regulating pluripotency of stem cells, MAPK signaling, Ras signaling pathways, EGFR tyrosine kinase inhibitor resistance, prostate cancer, viral protein interaction with cytokine and cytokine receptor, FoxO adhesion molecules, gastric cancer, proteoglycans in cancer, and endocytosis (Figure 2(b)).

3.3. Construction of the mRNA–miRNA Regulation Network and PPI Network. Three target prediction databases were employed to identify the target genes of selected DE-miRNAs. In total, 37 miRNAs were identified for 88 DE-miRNAs, which had different expression levels between patients with primary prostate cancer and patients with prostate cancer bone metastasis. In addition, 13 of the target
Significant GO terms

Positive regulation of cardiac muscle tissue development
Animal organ development
Regulation of muscle cell differentiation
Positive regulation of muscle tissue development
Positive regulation of cardiac muscle cell differentiation
Positive regulation of striated muscle tissue development
Regulation of cardiac muscle tissue development
Positive regulation of muscle cell differentiation
Muscle hypertrophy
Embryonic organ morphogenesis
Embryonic skeletal system morphogenesis
Positive regulation of heart growth
Positive regulation of cell proliferation in bone marrow
Bone development
Bone morphogenesis
Collagen−containing extracellular matrix
Desmosome
Extracellular exosome
Extracellular vesicle
Integral component of plasma membrane
Focal adhesion
Cell−substrate adherens junction
Intrinsic component of plasma membrane
Cornified envelope
Vesicle
Integral component of synaptic membrane
Lysosome
Integral component of presynaptic membrane
Integral component of postsynaptic specialization membrane
Vacuole
Extracellular matrix structural constituent conferring compression
Peptide transmembrane transporter activity
Protein homodimerization activity
Enhancer binding
Retinoid binding
Aminopeptidase activity
Voltage−gated potassium channel activity
Cadherin binding
RNA polymerase II distal enhancer sequence−specific DNA binding
Exopeptidase activity
Enhancer sequence−specific DNA binding
Hormone activity
Potassium channel activity
RNA polymerase II proximal promoter sequence−specific DNA binding
Ribonuclease activity

Transcriptional misregulation in cancer
Parathyroid hormone synthesis secretion and action
Signaling pathways regulating pluripotency of stem cells
Rap1 signaling pathway
EGFR tyrosine kinase inhibitor resistance
Ras signaling pathway
Endocrine resistance
Prostate cancer
Viral protein interaction with cytokine and cytokine receptor
MAPK signaling pathway
FoxO signaling pathway
Cell adhesion molecules (CAMs)
Gastric cancer
Proteoglycans in cancer
Endocytosis

Figure 2: Visualizations of pathway and process enrichment analysis results of DEGs. (a) GO term analysis of DEGs. The vertical axis represents the enrichment score value enriched on the GO term item, and the horizontal axis represents the name of the corresponding GO term item in the GO database. The figure only shows the top 15 terms of each category. BP: biological process; CC: cellular component; MF: molecular function. (b) KEGG enrichment analysis of DEGs. The top 15 clusters with their representative KEGG pathways. The color changes gradually from blue to red, which represents the significant level of enrichment to the pathway, and the redder the color, the greater the significance. The horizontal axis represents the enrichment score of the pathway, the vertical axis represents the corresponding pathway name in the KEGG database, and the size of the circle represents the number of genes enriched in the pathway.
Figure 3: The landscape of mRNA–miRNA interactions and PPI networks. (a) mRNA–miRNA interaction network. The graphic visualization uses different shapes representing different gene types: oval represents mRNA, and square represents miRNA. Different colors represent different gene expressions: blue represents downregulated genes, and red represents upregulated genes. (b) Differential expression of MEF2C in bone metastatic and nonbone metastatic prostate and breast cancers. The expression of miR-524-5p in bone metastatic and nonbone metastatic prostate cancer. (c) Protein–protein interaction (PPI) network of DEGs. The globules represent proteins, and the line between the globules represents the interaction between the two proteins.
genes (MEF2C, ZC3H7B, HOXB7, MAFB, GART, CD163, RAPGEF5, DHX9, MXRA5, MMP16, GJA1, PRKCA, ASPN) were upregulated, and one was downregulated. Thirty-seven DE-miRNAs and 14 target genes were identified in the miRNA–mRNA regulatory network, as shown in Figure 3(a). Among those DEGs, MEF2C showed the extremely high expression in patients with bone metastatic prostate and breast cancer (Figure 3(b)). Notably, MEF2C was one of the targets of miR-524-5p.

PPI networks were constructed through the string database from 13 proteins (confidence level of 0.4) consisting of 13 nodes and 14 edges for the DEGs in bone metastasis. The PPI network analysis showed that MEF2C, FGFR2, IGF1, and NCAM1 were hub genes (Figure 3(c)).

3.4. miR-524-5p Overexpression Restored Cell Proliferation and Invasion in Prostate and Breast Cancer. miR-524-5p was found to be one of the most significantly downregulated genes (MEF2C, ZC3H7B, HOXB7, MAFB, GART, CD163, RAPGEF5, DHX9, MXRA5, MMP16, GJA1, PRKCA, ASPN) were upregulated, and one was downregulated. Thirty-seven DE-miRNAs and 14 target genes were identified in the miRNA–mRNA regulatory network, as shown in Figure 3(a). Among those DEGs, MEF2C showed the extremely high expression in patients with bone metastatic prostate and breast cancer (Figure 3(b)). Notably, MEF2C was one of the targets of miR-524-5p.

PPI networks were constructed through the string database from 13 proteins (confidence level of 0.4) consisting of 13 nodes and 14 edges for the DEGs in bone metastasis. The PPI network analysis showed that MEF2C, FGFR2, IGF1, and NCAM1 were hub genes (Figure 3(c)).

3.4. miR-524-5p Overexpression Restored Cell Proliferation and Invasion in Prostate and Breast Cancer. miR-524-5p was found to be one of the most significantly downregulated
miRNAs in prostate and breast cancer with bone metastasis (Figures 3(a) and 3(b)). To further validate this result, the expression of miR-524-5p in the human prostate cancer cell lines DU145 and LNCAP and breast cancer cell line MCF7 was measured. qPCR showed that the expression of miR-524-5p was lower in MCF7 and DU145 cell lines than in LNCAP (Figure 4(a)).

To explore the biological function of miR-524-5p, miR-524-5p mimics were transfected into DU145 and MCF7 cell lines. The expression of miR-524-5p in DU145 and MCF7 cells was significantly increased in transfected cells (Figure 4(b)). In the CCK-8 assay, the cell proliferation ability of DU145 and MCF7 cells was inhibited by miR-524-5p mimics (Figure 4(c)). In the transwell assay, miR-524-5p mimics inhibited the migration ability of DU145 and MCF7 cells (Figure 4(d)).

3.5. miR-524-5p Specifically Targets MEF2C. MEF2C, a transcription factor, has been proposed as a new player in breast cancer brain metastasis development [33]. In contrast to
miR-524-5p, MEF2C was upregulated in prostate and breast cancer with bone metastasis, and the MEF2C gene was predicted to be a target for miR-631, miR-524-5p, miR-330-3p, and miR-346 (Figure 3(a)). qPCR results showed that MEF2C mRNA significantly decreased in cells transfected with miR-524-5p mimics compared with the NC group (Figure 5(a)), and Western blotting demonstrated that the MEF2C protein was also dramatically decreased (Figure 5(b)). The data indicated that MEF2C is most likely the target of miR-524-5p.

TargetScan predicted that there were binding sites of miR-524-5p in the 3′UTR of MEF2C at bases 130-136 (site 1) and 904-910 (site 2) (Figure 5(c)). To further confirm the inference that miR-524-5p targeted MEF2C, a luciferase reporter assay was conducted. For site 1, luciferase activities decreased in the cells cotransfected with wild-type MEF2C and miR-524-5p mimics compared with those in the NC group. However, there were no differences in the luciferase activities compared with their control group after cotransfection with MEF2C mutation (mut) and miR-524-5p mimics. For site 2, there was less change in the luciferase activities compared with those in their control group after cells were cotransfected with wild-type MEF2C and miR-524-5p mimics (Figure 5(d)). Therefore, MEF2C could be targeted by miR-524-5p through binding to both sites.

3.6. Effect of miR-524-5p on an In Vitro 3D Model of Prostate or Breast Cancer Bone Metastasis. Generally, the calvarial bone tissue was smooth and flat. However, in the model group cultured with DU145 or MCF7 cells, many DU145 or MCF7 cells obviously grew on the surface of calvarial bone. The number of DU145 or MCF7 cells on the calvarial bone was measured through crystal violet staining. The miR-524-5p mimics inhibited the growth of DU145 or MCF7 cells on the surface of the calvarial bone tissue (Figures 6(a) and 6(b)), which proved that the calvarial bone had strong adhesion to tumor cells. The adhered tumor cells caused damage to the calvarial bone in the coculture group. However, the overexpression of miR-524-5p repressed the adhesion and metastasis of tumor cells to bone tissue.

4. Discussion

As we described previously, bone is the most preferential metastatic site for prostate and breast cancer. Bone metastasis for prostate and breast cancer is a multistep process including tumor cell dissemination into the circulation, homing to the bone, and proliferation in bone tissue. A complicated network of molecular events plays an essential role in the development of bone metastasis. However, the underlying mechanism is not fully understood. In this study, a comprehensive genetic interaction network was established to explore the role of potential miRNAs, particularly miR-524-5p and its target MEF2C. We found that MEF2C was upregulated in bone metastasis development and regulated by miR-524-5p. These findings provide new insights into the altered miRNAs serving as potential biomarkers and MEF2C as a potential target for preventing or breaking prostate and breast cancer metastasis.

Several lines of literature have reported that miRNAs play a key role in cancer progression and metastasis. We found 11 downregulated miRNAs, including miR-524-5p, miR-330-3p, and miR-346, and 77 upregulated miRNAs,
such as miR-564, miR-602, and miR-129-5p, when searching for miRNAs with aberrant expression in prostate metastasis. Overexpressed miRNAs in various tumors have been found to be oncogenic miRNAs [34–37]. Other miRNAs with decreased expression are predicted to be tumor suppressors [38–40]. Among those miRNAs, as revealed by target prediction, miR-524-5p emerged as the most promising molecule and was reported to be involved in various cancers through different mechanisms. It has been predicted that miR-524-5p plays a tumor suppressor role in multiple types of cancers. Several studies have reported that miR-524-5p was downregulated in tumors, including glioma [41], colon cancer cells [13], gastric cancer [15], and papillary thyroid carcinoma [42], which can inhibit tumor proliferation and metastasis. In breast cancer, Jin et al. found that miR-524-5p inhibited the progression of migration, invasion, and epithelial–mesenchymal transition by targeting FSTL1 [18]. Consistent with Jin et al.’s result, our study confirmed that miR-524-5p was downregulated in prostate cancer bone metastasis compared to its expression in primary prostate cancer, and that the expression of miR-524-5p inhibited cell proliferation and invasion ability. The contradictions in previous reports may have arisen because a single miRNA can regulate various genes and functions or influence the expression of multiple factors in different cellular contexts [43].

The myocyte enhancer factor 2 (MEF2) protein family includes MEF2A, MEF2B, MEF2C, and MEF2D. MEF2C is widely expressed in muscle, neuronal, chondroid, immune, and endothelial cells [44]. In addition, MEF2C has close connections with uncontrolled cancer cell proliferation and enhanced invasion [45]. Regarding cancer metastasis, a recent study reported that MEF2C was consistently expressed in breast cancer brain metastases, and that its nuclear translocation was related to brain metastatic disease severity via VEGFR-2 and β-catenin signaling [46]. MEF2C was predicted to be regulated by miR-802-5p and miR-194-5p in brain metastases of breast cancer, which indicates that MEF2C plays a role in tumor metastasis. In this study, we found that MEF2C is upregulated in prostate and breast cancer bone metastasis. MEF2C was regulated by miR-524-5p, which was confirmed by luciferase assays and in vitro experiments. The absence of miR-524-5p in primary cancer tissue may promote bone metastasis through the upregulation of MEF2C. However, the specific downstream mechanism involved needs to be further investigated. Collectively, downregulation of miR-524-5p appears to be a precocious event in prostate and breast cancer, and MEF2C serves as a new player in prostate and cancer bone metastasis development.

Data Availability

The miRNA microarray data (GSE26964) and mRNA microarray data (GSE137842, GSE32269) used to support the findings of this study have been deposited in the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/) in NCBI.

Disclosure

A preprint has previously been published [47].

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This work was sponsored by grant National Natural Scientific Fund of China (grant numbers 81701798, 81703751), Natural Fund from Shanghai Science And Technology Commission (grant numbers 18ZR1429400, 19411971800), and Natural Fund from Shanghai Municipal Health Commission (grant number 202040340), China.

Supplementary Materials

Supplementary 1. Table S1: list of upregulated expressed miRNAs in breast cancer bone metastasis samples from the GSE137842 dataset.

Supplementary 2. Table S2: list of downregulated expressed miRNAs in breast cancer bone metastasis samples from the GSE137842 dataset.

Supplementary 3. Table S3: list of upregulated expressed miRNAs in prostate cancer bone metastasis samples from the GSE32269 dataset.

Supplementary 4. Table S4: list of downregulated expressed miRNAs in prostate cancer bone metastasis samples from the GSE32269 dataset.

Supplementary 5. Table S5: list of upregulated expressed miRNAs in prostate cancer bone metastatic samples from the GSE26964 dataset.

Supplementary 6. Table S6: list of downregulated expressed miRNAs in prostate cancer bone metastatic samples from the GSE26964 dataset.

References

[1] G. P. Risbridger, I. D. Davis, S. N. Birrell, and W. D. Tilley, “Breast and prostate cancer: more similar than different,” Nature Reviews Cancer, vol. 10, no. 3, pp. 205–212, 2010.

[2] R. K. Hernandez, S. W. Wade, A. Reich, M. Pirolli, A. Liede, and G. H. Lyman, “Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States,” BMC Cancer, vol. 18, no. 1, p. 44, 2018.

[3] H. G. Welch, D. H. Gorski, and P. C. Albertsen, “Trends in metastatic breast and prostate cancer—lessons in cancer dynamics,” The New England Journal of Medicine, vol. 373, no. 18, pp. 1685–1687, 2015.

[4] R. R. Langley and I. J. Fidler, “The seed and soil hypothesis revisited—the role of tumor-stroma interactions in metastasis to different organs,” International Journal of Cancer, vol. 128, no. 11, pp. 2527–2535, 2011.

[5] C. Liu, L. Wang, J. Zhuang et al., “Should de-escalation of bone-targeting agents be standard of care for patients with
bone metastases from breast cancer? A systematic review and meta-analysis,” *Annals of Oncology*, vol. 29, no. 5, pp. 1329–1330, 2018.

[6] F. Saad, A. Lipton, R. Cook, Y. M. Chen, M. Smith, and R. Coleman, “Pathologic fractures correlate with reduced survival in patients with malignant bone disease,” *Cancer*, vol. 110, no. 8, pp. 1860–1867, 2007.

[7] M. Esposito, T. Guise, and Y. Kang, “The Biology of Bone Metastasis,” Cold Spring Harbor Perspectives in Medicine, vol. 8, no. 6, 2018.

[8] F. Wahid, A. Shehzad, T. Khan, and Y. Y. Kim, “MicroRNAs: synthesis, mechanism, function, and recent clinical trials,” *Biochimica et Biophysica Acta*, vol. 1803, no. 11, pp. 1231–1243, 2010.

[9] Y. S. Lee and A. Dutta, “MicroRNAs in cancer,” *Annual Review of Pathology*, vol. 4, no. 1, pp. 199–227, 2009.

[10] H. Kishi and H. Taipaleenmäki, “MicroRNAs in bone metastasis,” *Current Osteoporosis Reports*, vol. 17, no. 3, pp. 122–128, 2019.

[11] W. L. Cai, W. D. Huang, B. Li et al., “microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11,” *Molecular cancer*, vol. 17, no. 1, p. 9, 2018.

[12] Y. Tang, J. Pan, S. Huang et al., “Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling,” *Journal of Experimental & Clinical Cancer Research*, vol. 37, no. 1, p. 160, 2018.

[13] X. Li, Z. Li, Y. Zhu et al., “miR-524-5p inhibits angiogenesis through targeting WNK1 in colon cancer cells,” *American Journal of Physiology. Gastrointestinal and Liver Physiology*, vol. 318, no. 4, pp. G827–g839, 2020.

[14] M. T. Nguyen, C. H. Lin, S. M. Liu et al., “miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma,” *Neoplasia*, vol. 22, no. 12, pp. 789–799, 2020.

[15] C. Y. Zhu, F. Q. Meng, and J. Liu, “MicroRNA-524-5p suppresses cell proliferation and promotes cell apoptosis in gastric cancer by regulating CASP3,” *European Review for Medical and Pharmacological Sciences*, vol. 23, no. 18, pp. 7968–7977, 2019.

[16] H. Yang, C. Cao, and L. J. Wang, “LncRNA LINC-PINT regulating proliferation and apoptosis of osteosarcoma cells by targeting miR-524-5p,” *Zhonghua Zhong Liu Za Zhi*, vol. 42, no. 4, pp. 325–330, 2020.

[17] L. Chen, G. Wang, X. Qiao et al., “Downregulated miR-524-5p participates in the tumor microenvironment of Ameloblastoma by targeting the Interleukin-33 (IL-33)/suppression of Tumorigenicity 2 (ST2) Axis,” *Medical Science Monitor*, vol. 26, article e921863, 2020.

[18] T. Jin, Y. Zhang, and T. Zhang, “miR-524-5p suppresses migration, invasion, and EMT progression in breast cancer cells through targeting FSTL1,” *Cancer Biotherapy & Radiopharmaceuticals*, vol. 35, no. 10, pp. 789–801, 2020.

[19] C. Cai, H. Wang, H. H. He et al., “ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer,” *The Journal of Clinical Investigation*, vol. 125, no. 3, pp. 1109–1122, 2013.

[20] D. Leley, F. Howard, F. Arshad et al., “Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts,” *Breast Cancer Research*, vol. 21, no. 1, 2019.

[21] X. S. Peng, W. Guo, T. Liu et al., “Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT,” *PLoS One*, vol. 6, no. 5, 2011.

[22] R. A. Irizarry, B. Hobbs, F. Collin et al., “Exploration, normalization, and summaries of high density oligonucleotide array probe level data,” *Biostatistics*, vol. 4, no. 2, pp. 249–264, 2003.

[23] M. E. Ritchie, B. Hipponen, D. Wu et al., “limma powers differential expression analyses for RNA-sequencing and microarray studies,” *Nucleic acids research*, vol. 43, no. 7, p. e47, 2015.

[24] G. Dennis, B. T. Sherman, D. A. Hosack et al., “DAVID: Database for Annotation, Visualization, And Integrated Discovery,” *Genome Biology*, vol. 4, no. 5, p. P3, 2003.

[25] D. Lai, L. Tan, X. Zuo et al., “Prognostic ferroptosis-related lncRNA signatures associated with immunotherapy and chemotherapy responses in patients with stomach cancer,” *Frontiers in Genetics*, vol. 12, article 798612, 2021.

[26] Gene Ontology Consortium, “The Gene Ontology (GO) project in 2006,” *Nucleic Acids Research*, vol. 34, no. 9, pp. D322–D326, 2006.

[27] H. Ogata, S. Goto, K. Sato, W. Fujibuchi, H. Bono, and M. Kanehisa, “KEGG: Kyoto Encyclopedia Of Genes And Genomes,” *Nucleic Acids Research*, vol. 27, no. 1, pp. 29–34, 1999.

[28] P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” *Genome Research*, vol. 13, no. 11, pp. 2498–2504, 2003.

[29] P. Curtin, H. Youm, and E. Salih, “Three-dimensional cancer-bone metastasis model using ex-vivo co-cultures of live calvarial bones and cancer cells,” *Biomaterials*, vol. 33, no. 4, pp. 1065–1078, 2012.

[30] R. Alfred, J. T. Taiani, R. J. Krawetz, A. Yamashita, D. E. Rancourt, and M. S. Kallos, “Large-scale production of murine embryonic stem cell-derived osteoblasts and chondrocytes on microcarriers in serum-free media,” *Biomaterials*, vol. 32, no. 26, pp. 6006–6016, 2011.

[31] Y. P. Zhao, W. L. Ye, D. Z. Liu et al., “Redox and pH dual sensitive bone targeting nanoparticles to treat breast cancer bone metastases and inhibit bone resorption,” *Nanoscale*, vol. 9, no. 19, pp. 6264–6277, 2017.

[32] K. Chen, D. Shen, L. Tan et al., “A pan-cancer analysis reveals the prognostic and immunotherapeutic value of ALKBH7,” *Frontiers in Genetics*, vol. 13, p. 82261, 2022.

[33] M. Sereno, J. Haskó, K. Molnár et al., “Downregulation of circulating miR 802-5p and miR 194-5p and upregulation of brain MEF2C along breast cancer brain metastasization,” *Molecular Oncology*, vol. 14, no. 3, pp. 520–538, 2020.

[34] L. He, J. M. Thomson, M. T. Hemann et al., “A microRNA polycistron as a potential human oncogene,” *Nature*, vol. 435, no. 7043, pp. 828–833, 2005.

[35] S. Costinean, N. Zanesi, Y. Pekarsky et al., “Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice,” *The National Academy of Sciences of the United States of America*, vol. 103, no. 18, pp. 7024–7029, 2006.

[36] A. Esquela-Kerscher and F. J. Slack, “Oncomirs - microRNAs with a role in cancer,” *Nature Reviews Cancer*, vol. 6, no. 4, pp. 259–269, 2006.

[37] P. M. Voorhoeve, C. le Sage, M. Schrier et al., “A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors,” *Cell*, vol. 124, no. 6, pp. 1169–1181, 2006.
[38] G. A. Calin, C. D. Dumitru, M. Shimizu et al., “Frequent deletions and down-regulation of micro-RNA genes miR15- and miR16 at 13q14 in chronic lymphocytic leukemia,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 24, pp. 15524–15529, 2002.

[39] N. Yanaihara, N. Caplen, E. Bowman et al., “Unique micro-RNA molecular profiles in lung cancer diagnosis and prognosis,” *Cancer Cell*, vol. 9, no. 3, pp. 189–198, 2006.

[40] C. Welch, Y. Chen, and R. L. Stallings, “MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells,” *Oncogene*, vol. 26, no. 34, pp. 5017–5022, 2007.

[41] L. C. Chen, W. Zhang, W. Yan et al., “The putative tumor suppressor miR-524-5p directly targets Jagged-1 and Hes-1 in glioma,” *Carcinogenesis*, vol. 33, no. 11, pp. 2276–2282, 2012.

[42] H. Liu, X. Chen, T. Lin, X. Chen, J. Yan, and S. Jiang, “Micro-RNA-524-5p suppresses the progression of papillary thyroid carcinoma cells via targeting on FOXE1 and ITGA3 in cell autophagy and cycling pathways,” *Journal of Cellular Physiology*, vol. 234, no. 10, pp. 18382–18391, 2019.

[43] D. M. Dykxhoorn, “MicroRNAs and metastasis: little RNAs go a long way,” *Cancer Research*, vol. 70, no. 16, pp. 6401–6406, 2010.

[44] C. Dong, X. Z. Yang, C. Y. Zhang et al., “Myocyte enhancer factor 2C and its directly-interacting proteins: a review,” *Progress in Biophysics and Molecular Biology*, vol. 126, pp. 22–30, 2017.

[45] J. H. Ostrander, A. R. Daniel, K. Lofgren, C. G. Kleer, and C. A. Lange, “Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells,” *Cancer Research*, vol. 67, no. 9, pp. 4199–4209, 2007.

[46] S. Takashima, S. Usui, O. Inoue et al., “Myocyte-specific enhancer factor 2c triggers transdifferentiation of adipose tissue-derived stromal cells into spontaneously beating cardiomyocyte-like cells,” *Scientific Reports*, vol. 11, no. 1, p. 1520, 2021.

[47] Q. Tian, Y. Lu, B. Yan, and C. G. Wu, *Integrative Bioinformatics Analysis Reveals miR-524-5p/MEF2C Regulates Bone Metastasis in Prostate Cancer and Breast Cancer*, 2021.